Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Half-Dose Radiopharmaceutical in Wide Beam Reconstruction (REGA-1102)

This study has been terminated.
(Low enrollment)
Astellas Pharma Global Development, Inc.
Information provided by (Responsible Party):
Edwin Wu, Northwestern University Identifier:
First received: December 19, 2011
Last updated: January 27, 2016
Last verified: January 2016
Results First Received: December 18, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Conditions: Myocardial Infarction
Ischemic Heart Disease
Intervention: Drug: Half-dose of the Tc99-m sestamibi (Cardiolite)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Prospectively enroll patients with history of severe myocardial infarction, cardiomyopathy, heart failure or prior nuclear scans with resting perfusion defects. Patients were approached in the nuclear stress lab prior to scheduled stress test. Recruitment period was between 3/20/2012 and 2/14/2014.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Study Group Entire cohort

Participant Flow:   Overall Study
    Study Group  
STARTED     64  
COMPLETED     64  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Study Group Entire cohort

Baseline Measures
    Study Group  
Number of Participants  
[units: participants]
[units: years]
Mean (Standard Deviation)
  66  (11)  
[units: participants]
Female     16  
Male     48  
[units: inches]
Mean (Standard Deviation)
  68.0  (4.1)  
[units: pounds]
Mean (Standard Deviation)
  198.4  (40.0)  
Body mass index  
[units: kg/m^2]
Mean (Standard Deviation)
  30.2  (6.0)  
Indications for stress test  
[units: participants]
Chest pain     16  
Dyspnea     9  
Prior Myocardial Infarct     7  
Prior Coronary Disease     18  
Cardiomyopathy     5  
CHF     6  
Prior CABG     8  
Prior PCI     5  
Other     9  
[units: participants]
Hypertension     58  
Hypercholesterolemia     52  
Tobacco smoking (prior or current)     24  
Diabetes mellitus     21  
Family history of CAD     19  
Prior Myocardial Infarct     28  
Coronary artery disease     46  
Coronary artery bypass surgery     27  
Previous nuclear stress  
[units: participants]
[units: participants]
ACE inhibitors/ARB     33  
Beta-blockers     56  
Ca-channel blockers     19  
Aspirin     51  
Anti-platelet     21  
Statin     53  
Nitrates     11  
Diuretic     24  

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Sum Rest Score   [ Time Frame: Baseline ]

2.  Primary:   Segments With Resting Perfusion Defect   [ Time Frame: Baseline ]

3.  Secondary:   Image Quality Score   [ Time Frame: Baseline ]

4.  Secondary:   Diagnostic Confidence Score   [ Time Frame: Baseline ]

5.  Post-Hoc:   Resting Full-Tracer Dose   [ Time Frame: Baseline ]

6.  Post-Hoc:   Injection and Scan Times   [ Time Frame: Baseline ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Early termination of study lead to a small numbers of subjects analyzed. Technical problems in WBR processing settings including acquisition matrix sizes and/or number of iterations.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Edwin Wu, MD
Organization: Northwestern University
phone: 847-535-7270

Responsible Party: Edwin Wu, Northwestern University Identifier: NCT01499654     History of Changes
Other Study ID Numbers: STU53243
Study First Received: December 19, 2011
Results First Received: December 18, 2015
Last Updated: January 27, 2016
Health Authority: United States: Institutional Review Board